|
EP2340309A2
(en)
|
2008-09-22 |
2011-07-06 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
|
BR112012024049A2
(pt)
|
2010-03-24 |
2017-03-01 |
Rxi Pharmaceuticals Corp |
interferência de rna em indicações dérmicas e fibróticas
|
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
CA3044664C
(en)
|
2016-11-30 |
2022-11-22 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
DK3579848T3
(da)
|
2017-02-08 |
2025-01-20 |
Dragonfly Therapeutics Inc |
Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
|
|
KR20240060739A
(ko)
|
2017-02-20 |
2024-05-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Her2, nkg2d 및 cd16에 결합하는 단백질
|
|
EP3615070A1
(en)
|
2017-04-26 |
2020-03-04 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CA3061050A1
(en)
*
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
|
MX2019014265A
(es)
|
2017-06-01 |
2020-08-03 |
Compugen Ltd |
Tratamientos conjuntos triples con anticuerpos.
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
EP3664817A4
(en)
*
|
2017-08-07 |
2021-09-22 |
Phio Pharmaceuticals Corp. |
CHEMICALLY MODIFIED OLIGONUCLEOTIDES
|
|
WO2019037052A1
(zh)
*
|
2017-08-24 |
2019-02-28 |
深圳市博奥康生物科技有限公司 |
靶向沉默wucam的shrna
|
|
CN108558997B
(zh)
*
|
2017-10-20 |
2021-10-08 |
中国人民解放军第四军医大学 |
一种重组融合蛋白TIGIT-Fc及其抗移植排斥反应的应用
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
SG11202007579TA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
MX2020008795A
(es)
|
2018-02-28 |
2020-10-08 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
WO2019178356A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Dana-Farber Cancer Institute, Inc. |
Engineered cells, t cell immune modulating antibodies and methods for using the same
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EP3833385A4
(en)
|
2018-08-08 |
2021-12-22 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
|
|
BR112021003156A2
(pt)
|
2018-08-23 |
2021-05-11 |
Seagen, Inc. |
composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
|
|
KR102084196B1
(ko)
*
|
2018-08-29 |
2020-03-03 |
연세대학교 산학협력단 |
면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
WO2020102387A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
US20220362333A1
(en)
*
|
2019-07-26 |
2022-11-17 |
Board Of Trustees Of Michigan State University |
Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
|
|
EP4041392A1
(en)
*
|
2019-10-08 |
2022-08-17 |
Nectin Therapeutics Ltd. |
Antibodies against the poliovirus receptor (pvr) and uses thereof
|
|
JP2023502585A
(ja)
*
|
2019-11-05 |
2023-01-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
|
|
US20230057899A1
(en)
|
2019-12-05 |
2023-02-23 |
Compugen Ltd. |
Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
|
|
WO2021142088A1
(en)
*
|
2020-01-07 |
2021-07-15 |
The Trustees Of The University Of Pennsylvania |
Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
|
|
CN115916247B
(zh)
*
|
2020-04-19 |
2025-04-01 |
奥美药业有限公司 |
人tigit特异性单域抗体及其应用
|
|
CN115836088A
(zh)
|
2020-05-06 |
2023-03-21 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和clec12a的蛋白质
|
|
CN115916348A
(zh)
|
2020-06-18 |
2023-04-04 |
基因泰克公司 |
使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
|
|
CN111763660A
(zh)
*
|
2020-08-07 |
2020-10-13 |
南京大学 |
一种重组溶瘤痘苗病毒及其制备方法和应用
|
|
WO2022155518A1
(en)
|
2021-01-15 |
2022-07-21 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
MX2023009113A
(es)
|
2021-02-03 |
2023-08-10 |
Seagen Inc |
Conjugados y compuestos inmunoestimulantes.
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
CN113030487B
(zh)
*
|
2021-03-31 |
2023-11-10 |
山东大学齐鲁医院 |
Cd155在宫颈癌诊治中的应用
|
|
TW202304965A
(zh)
|
2021-05-04 |
2023-02-01 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
|
|
TW202320848A
(zh)
|
2021-07-28 |
2023-06-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
CA3229166A1
(en)
*
|
2021-08-20 |
2023-02-23 |
Zhongmin Wang |
Fusion protein containing anti-tigit antibody and tgf-?r, and pharmaceutical composition and use thereof
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
KR102680316B1
(ko)
*
|
2021-11-01 |
2024-07-01 |
오토텔릭바이오 주식회사 |
안티센스 올리고뉴클레오타이드
|
|
AU2023236289A1
(en)
|
2022-03-15 |
2024-08-15 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
CN115043910B
(zh)
*
|
2022-03-25 |
2023-04-07 |
湖南中晟全肽生化有限公司 |
抑制tigit与cd155结合的多肽及其应用
|
|
CA3252067A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory Antibody-Drug Conjugates
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
AU2023320054A1
(en)
|
2022-08-03 |
2025-02-06 |
Regents Of The University Of Minnesota |
Immunostimulatory anti-pd-l1-drug conjugates
|
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
|
CN116284395B
(zh)
*
|
2022-12-12 |
2024-11-08 |
合肥天港免疫药物有限公司 |
抗cd155的抗体及其应用
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|